Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Prevacid poised for launch

This article was originally published in The Tan Sheet

Executive Summary

An 1advertisement in the Oct. 23 issue of All You magazine says Novartis' Prevacid 24HR could be "available as early as November 12th." The Web site for the proton pump inhibitor, 2www.prevacid24hr.com, has been updated with additional information about the product, including packaging and drug facts. Novartis, which licenses Prevacid 24HR (lansoprazole 15 mg) from Takeda Pharmaceuticals, appears to position the drug as an alternative to prescription heartburn remedies, rather than attempting to draw away users of Procter & Gamble's Prilosec OTC (omeprazole 20 mg) - as the company said upon FDA approval of the switch in May (3"The Tan Sheet" May 18, 2009). The OTC PPI market may grow more crowded after December, when FDA's decision on Santarus/Schering-Plough's Zegerid (omeprazole 20 mg/sodium bicarbonate) is due (4"The Tan Sheet" June 29, 2009, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel